576 / 1674
•
3451 patients recruited between 2000 and 2012
•
Prepathology stratum (n=2298):
TARGIT 2.1% versus EBRT 1.1% (p=0.31)
PgR+ predictor of outcome
•
Postpathology stratum (n=1153):
•
TARGIT 5.4% versus EBRT 1.7% (p0.069)
•
Less non-breast cancer-deaths: 1.4% vs 3.5%
Vaidya JS et al, Health Tecnol Assess 2016